CStone Pharmaceuticals
Executives
View the org chart displaying its 5 main executives
Most searched biographies at CStone Pharmaceuticals
- Jason Yang, Chief Executive Officer
- Archie Tse, Chief Scientific Officer
- Jun Cheng, Vice President, Finance
Create your alert
to follow the executive moves at CStone Pharmaceuticals.
Pharmaceuticals
CStone Pharmaceuticals has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by CStone Pharmaceuticals
- CStone Announces the Acceptance of GAVRETO® (pralsetinib) Manufacturing Localization Application by Center for Drug Evaluation of China NMPA-CStone Pharmaceuticals
- CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates-CStone Pharmaceuticals
- CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer-CStone Pharmaceuticals
- CStone Announces Publication in Clinical Cancer Research with AYVAKIT® (Avapritinib) Data in Patients with Advanced Gastrointestinal Stromal Tumors-CStone Pharmaceuticals
- CStone Announces the Latest Business Update-CStone Pharmaceuticals
- CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore-CStone Pharmaceuticals
- CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma-CStone Pharmaceuticals
- CStone’s Partner Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)-CStone Pharmaceuticals
- CStone Showcased, in an Oral Session, Late-breaking Results from Phase 3 Study of Sugemalimab in First-Line Gastric or Gastroesophageal Junction Adenocarcinoma at ESMO 2023-CStone Pharmaceuticals
- CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication-CStone Pharmaceuticals
- View more press releases Close
Social media about CStone Pharmaceuticals
- CStone Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- CStone Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Archie Tse 
Call CStone Pharmaceuticals at +1 512 ...
